share_log
Breakings ·  Jan 7 22:15
Recursion Pharmaceuticals Inc - First Patient to Be Dosed in Phase 1 Excelerize Trial in Q1 2025
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment